Role of GLP-1 receptor agonists in COPD exacerbation

Creative Commons License

Çakır A., Memiş H.

3rd International Aegean Health Areas Symposium 2023, Uşak, Turkey, 07 March 2023, pp.142-146

  • Publication Type: Conference Paper / Full Text
  • City: Uşak
  • Country: Turkey
  • Page Numbers: pp.142-146
  • Inonu University Affiliated: Yes


Chronic obstructive pulmonary disease (COPD) is a pulmonary disease characterized by chronic respiratory symptoms dependent on the anomalies of the airway causing air flow obstruction. In some cases, respiratory distress could result in mortality. Compared to the general population, it is known that patients with acute COPD exacerbations have a higher prevalence of type 2 diabetes mellitus (T2DM), and in addition to that, uncontrolled blood sugar levels increase the risk of death in patients with acute COPD exacerbations. Many studies have shown that glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat diabetes, improve respiratory function in patients with COPD exacerbation. While antidiabetic therapy is being considered in patients with DM, this situation could be considered. GLP-1 receptor agonists may reduce COPD complications and shorten the duration of hospitalization for patients with COPD exacerbation. These agents could be a new preference in the prevention and treatment of COPD. In addition, there are studies showing that GLP-1 receptor agonists may be beneficial in patients without DM who experience COPD exacerbations. The aim of this study is to search for related studies showing that GLP-1 receptor agonists are effective in COPD exacerbation, to draw attention to this area, and to pioneer future studies on this subject.